Insights into RNA N6-methyladenosine in Glucose and Lipid Metabolic Diseases and Their Therapeutic Strategies
Abstract The incidence of glucose and lipid metabolism diseases, including type 2 diabetes, obesity, metabolic syndrome, and nonalcoholic fatty liver disease, is rising, which places an enormous burden on people around the world. However, the mechanism behind these disorders remains incompletely und...
Gespeichert in:
| Veröffentlicht in: | Endocrinology (Philadelphia) 2023-11, Vol.165 (1) |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | |
| container_title | Endocrinology (Philadelphia) |
| container_volume | 165 |
| creator | Wu, Yifan Zeng, Yuan Ren, Yaolin Yu, Jie Zhang, Qian Xiao, Xinhua |
| description | Abstract
The incidence of glucose and lipid metabolism diseases, including type 2 diabetes, obesity, metabolic syndrome, and nonalcoholic fatty liver disease, is rising, which places an enormous burden on people around the world. However, the mechanism behind these disorders remains incompletely understood. N6-methyladenosine (m6A) is 1 type of posttranscriptional RNA modification, and research has shown that it plays a crucial role in several metabolic diseases. m6A methylation is reversibly and dynamically regulated by methyltransferases (writers), demethylases (erasers), and m6A binding proteins (readers). Dysregulation of RNA m6A modification is related to different metabolic processes. Targeting RNA m6A methylation is a potential treatment strategy for these chronic metabolic diseases. This review discusses studies on RNA m6A modification in metabolic diseases and existing therapeutic drugs, with the aim of providing a concise perspective on its potential applications in managing metabolic disorders. |
| doi_str_mv | 10.1210/endocr/bqad170 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_oup_p</sourceid><recordid>TN_cdi_proquest_miscellaneous_2889243776</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1210/endocr/bqad170</oup_id><sourcerecordid>2889243776</sourcerecordid><originalsourceid>FETCH-LOGICAL-o180t-b20872b569e58f8e2ea80695ae9613e9ff9c4c997414a09eee2bac99d2746e8c3</originalsourceid><addsrcrecordid>eNpdkDtPwzAURi0EEqWwMltigSHUr8TxWBUolUqRoMyRk9y0rpI4jZ2h_x6XdmK5D31HV1cHoXtKnimjZAJtaYt-ku91SSW5QCOqRBzJMF-iESGUR5IxeY1unNuFVQjBR6hZtM5stt5h03qLv1ZTvEqiBvz2UOsSWutMCyHD83oorAOs2xIvTWdK_AFe57Y2BX4xDrQD9xeut2D6Y-11B4MP8bfvtYeNAXeLripdO7g79zH6eXtdz96j5ed8MZsuI0tT4qOckVSyPE4UxGmVAgOdkkTFGlRCOaiqUoUolJKCCk0UALBch71kUiSQFnyMHk93u97uB3A-a4wroK51C3ZwGUtTxQSXMgnowz90Z4e-Dd9lnHISlPGYB-rpRNmhy7reNLo_ZJRkR_HZSXx2Fs9_AVvmeIM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3130722353</pqid></control><display><type>article</type><title>Insights into RNA N6-methyladenosine in Glucose and Lipid Metabolic Diseases and Their Therapeutic Strategies</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Wu, Yifan ; Zeng, Yuan ; Ren, Yaolin ; Yu, Jie ; Zhang, Qian ; Xiao, Xinhua</creator><creatorcontrib>Wu, Yifan ; Zeng, Yuan ; Ren, Yaolin ; Yu, Jie ; Zhang, Qian ; Xiao, Xinhua</creatorcontrib><description>Abstract
The incidence of glucose and lipid metabolism diseases, including type 2 diabetes, obesity, metabolic syndrome, and nonalcoholic fatty liver disease, is rising, which places an enormous burden on people around the world. However, the mechanism behind these disorders remains incompletely understood. N6-methyladenosine (m6A) is 1 type of posttranscriptional RNA modification, and research has shown that it plays a crucial role in several metabolic diseases. m6A methylation is reversibly and dynamically regulated by methyltransferases (writers), demethylases (erasers), and m6A binding proteins (readers). Dysregulation of RNA m6A modification is related to different metabolic processes. Targeting RNA m6A methylation is a potential treatment strategy for these chronic metabolic diseases. This review discusses studies on RNA m6A modification in metabolic diseases and existing therapeutic drugs, with the aim of providing a concise perspective on its potential applications in managing metabolic disorders.</description><identifier>ISSN: 0013-7227</identifier><identifier>EISSN: 1945-7170</identifier><identifier>DOI: 10.1210/endocr/bqad170</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Diabetes mellitus (non-insulin dependent) ; Drug delivery ; Fatty liver ; Glucose ; Glucose metabolism ; Lipid metabolism ; Lipids ; Liver diseases ; Metabolic disorders ; Metabolic syndrome ; Methylation ; N6-methyladenosine ; Post-transcription ; RNA modification</subject><ispartof>Endocrinology (Philadelphia), 2023-11, Vol.165 (1)</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2023</rights><rights>The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0001-9846-0141 ; 0000-0001-5441-7766</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Wu, Yifan</creatorcontrib><creatorcontrib>Zeng, Yuan</creatorcontrib><creatorcontrib>Ren, Yaolin</creatorcontrib><creatorcontrib>Yu, Jie</creatorcontrib><creatorcontrib>Zhang, Qian</creatorcontrib><creatorcontrib>Xiao, Xinhua</creatorcontrib><title>Insights into RNA N6-methyladenosine in Glucose and Lipid Metabolic Diseases and Their Therapeutic Strategies</title><title>Endocrinology (Philadelphia)</title><description>Abstract
The incidence of glucose and lipid metabolism diseases, including type 2 diabetes, obesity, metabolic syndrome, and nonalcoholic fatty liver disease, is rising, which places an enormous burden on people around the world. However, the mechanism behind these disorders remains incompletely understood. N6-methyladenosine (m6A) is 1 type of posttranscriptional RNA modification, and research has shown that it plays a crucial role in several metabolic diseases. m6A methylation is reversibly and dynamically regulated by methyltransferases (writers), demethylases (erasers), and m6A binding proteins (readers). Dysregulation of RNA m6A modification is related to different metabolic processes. Targeting RNA m6A methylation is a potential treatment strategy for these chronic metabolic diseases. This review discusses studies on RNA m6A modification in metabolic diseases and existing therapeutic drugs, with the aim of providing a concise perspective on its potential applications in managing metabolic disorders.</description><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Drug delivery</subject><subject>Fatty liver</subject><subject>Glucose</subject><subject>Glucose metabolism</subject><subject>Lipid metabolism</subject><subject>Lipids</subject><subject>Liver diseases</subject><subject>Metabolic disorders</subject><subject>Metabolic syndrome</subject><subject>Methylation</subject><subject>N6-methyladenosine</subject><subject>Post-transcription</subject><subject>RNA modification</subject><issn>0013-7227</issn><issn>1945-7170</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpdkDtPwzAURi0EEqWwMltigSHUr8TxWBUolUqRoMyRk9y0rpI4jZ2h_x6XdmK5D31HV1cHoXtKnimjZAJtaYt-ku91SSW5QCOqRBzJMF-iESGUR5IxeY1unNuFVQjBR6hZtM5stt5h03qLv1ZTvEqiBvz2UOsSWutMCyHD83oorAOs2xIvTWdK_AFe57Y2BX4xDrQD9xeut2D6Y-11B4MP8bfvtYeNAXeLripdO7g79zH6eXtdz96j5ed8MZsuI0tT4qOckVSyPE4UxGmVAgOdkkTFGlRCOaiqUoUolJKCCk0UALBch71kUiSQFnyMHk93u97uB3A-a4wroK51C3ZwGUtTxQSXMgnowz90Z4e-Dd9lnHISlPGYB-rpRNmhy7reNLo_ZJRkR_HZSXx2Fs9_AVvmeIM</recordid><startdate>20231120</startdate><enddate>20231120</enddate><creator>Wu, Yifan</creator><creator>Zeng, Yuan</creator><creator>Ren, Yaolin</creator><creator>Yu, Jie</creator><creator>Zhang, Qian</creator><creator>Xiao, Xinhua</creator><general>Oxford University Press</general><scope>7QG</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9846-0141</orcidid><orcidid>https://orcid.org/0000-0001-5441-7766</orcidid></search><sort><creationdate>20231120</creationdate><title>Insights into RNA N6-methyladenosine in Glucose and Lipid Metabolic Diseases and Their Therapeutic Strategies</title><author>Wu, Yifan ; Zeng, Yuan ; Ren, Yaolin ; Yu, Jie ; Zhang, Qian ; Xiao, Xinhua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-o180t-b20872b569e58f8e2ea80695ae9613e9ff9c4c997414a09eee2bac99d2746e8c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Drug delivery</topic><topic>Fatty liver</topic><topic>Glucose</topic><topic>Glucose metabolism</topic><topic>Lipid metabolism</topic><topic>Lipids</topic><topic>Liver diseases</topic><topic>Metabolic disorders</topic><topic>Metabolic syndrome</topic><topic>Methylation</topic><topic>N6-methyladenosine</topic><topic>Post-transcription</topic><topic>RNA modification</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Yifan</creatorcontrib><creatorcontrib>Zeng, Yuan</creatorcontrib><creatorcontrib>Ren, Yaolin</creatorcontrib><creatorcontrib>Yu, Jie</creatorcontrib><creatorcontrib>Zhang, Qian</creatorcontrib><creatorcontrib>Xiao, Xinhua</creatorcontrib><collection>Animal Behavior Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Endocrinology (Philadelphia)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Yifan</au><au>Zeng, Yuan</au><au>Ren, Yaolin</au><au>Yu, Jie</au><au>Zhang, Qian</au><au>Xiao, Xinhua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insights into RNA N6-methyladenosine in Glucose and Lipid Metabolic Diseases and Their Therapeutic Strategies</atitle><jtitle>Endocrinology (Philadelphia)</jtitle><date>2023-11-20</date><risdate>2023</risdate><volume>165</volume><issue>1</issue><issn>0013-7227</issn><eissn>1945-7170</eissn><abstract>Abstract
The incidence of glucose and lipid metabolism diseases, including type 2 diabetes, obesity, metabolic syndrome, and nonalcoholic fatty liver disease, is rising, which places an enormous burden on people around the world. However, the mechanism behind these disorders remains incompletely understood. N6-methyladenosine (m6A) is 1 type of posttranscriptional RNA modification, and research has shown that it plays a crucial role in several metabolic diseases. m6A methylation is reversibly and dynamically regulated by methyltransferases (writers), demethylases (erasers), and m6A binding proteins (readers). Dysregulation of RNA m6A modification is related to different metabolic processes. Targeting RNA m6A methylation is a potential treatment strategy for these chronic metabolic diseases. This review discusses studies on RNA m6A modification in metabolic diseases and existing therapeutic drugs, with the aim of providing a concise perspective on its potential applications in managing metabolic disorders.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1210/endocr/bqad170</doi><orcidid>https://orcid.org/0000-0001-9846-0141</orcidid><orcidid>https://orcid.org/0000-0001-5441-7766</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0013-7227 |
| ispartof | Endocrinology (Philadelphia), 2023-11, Vol.165 (1) |
| issn | 0013-7227 1945-7170 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2889243776 |
| source | Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Diabetes mellitus (non-insulin dependent) Drug delivery Fatty liver Glucose Glucose metabolism Lipid metabolism Lipids Liver diseases Metabolic disorders Metabolic syndrome Methylation N6-methyladenosine Post-transcription RNA modification |
| title | Insights into RNA N6-methyladenosine in Glucose and Lipid Metabolic Diseases and Their Therapeutic Strategies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T11%3A30%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_oup_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insights%20into%20RNA%20N6-methyladenosine%20in%20Glucose%20and%20Lipid%20Metabolic%20Diseases%20and%20Their%20Therapeutic%20Strategies&rft.jtitle=Endocrinology%20(Philadelphia)&rft.au=Wu,%20Yifan&rft.date=2023-11-20&rft.volume=165&rft.issue=1&rft.issn=0013-7227&rft.eissn=1945-7170&rft_id=info:doi/10.1210/endocr/bqad170&rft_dat=%3Cproquest_oup_p%3E2889243776%3C/proquest_oup_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3130722353&rft_id=info:pmid/&rft_oup_id=10.1210/endocr/bqad170&rfr_iscdi=true |